57728-67-3

Basic information

• Product Name: 4-BROMO-N-(2-HYDROXYETHYL)BENZENECARBOXAMIDE
• Synonyms: 4-BROMO-N-(2-HYDROXYETHYL)BENZENECARBOXAMIDE
• CAS NO: 57728-67-3
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.09
• Mol File: 57728-67-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 146-147°
• Boiling Point: 417.1 °C at 760 mmHg
• Flash Point: 206 °C
• Appearance: /
• Density: 1.525 g/cm³
• Vapor Pressure: 1.05E-07mmHg at 25°C
• Refractive Index: 1.586
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-BROMO-N-(2-HYDROXYETHYL)BENZENECARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-N-(2-HYDROXYETHYL)BENZENECARBOXAMIDE(57728-67-3)
• EPA Substance Registry System: 4-BROMO-N-(2-HYDROXYETHYL)BENZENECARBOXAMIDE(57728-67-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 57728-67-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-N-(2-hydroxyethyl)benzenecarboxamide is a chemical compound with the molecular formula C9H10BrNO2. It is an amide derivative of bromobenzene with a hydroxyethyl group attached to the nitrogen atom. 4-BROMO-N-(2-HYDROXYETHYL)BENZENECARBOXAMIDE is often used as a building block in organic synthesis and pharmaceutical research due to its versatile reactivity and potential as a scaffold for drug design. It may also have potential applications in the development of new materials and chemical processes. Additionally, 4-Bromo-N-(2-hydroxyethyl)benzenecarboxamide is considered to be a hazardous substance and should be handled with caution due to its potential health and environmental risks.

InChI:InChI=1/C9H10BrNO2/c10-8-3-1-7(2-4-8)9(13)11-5-6-12/h1-4,12H,5-6H2,(H,11,13)

Upstream product

• 18292-63-2 1-(p-bromobenzoyl)aziridine 
• 586-76-5 4-Bromobenzoic acid 
• 141-43-5 ethanolamine 
• 951885-58-8 2-(4-bromobenzamido)ethyl 4-bromobenzoate 
• 586-75-4 4-chlorobenzoyl chloride 
• 623-00-7 4-bromobenzenecarbonitrile 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 619-42-1 4-methoxycarbonylphenyl bromide 

Downstream Products

• 1073353-51-1 N-(2-hydroxyethyl)benzamide-4-boronic acid pinacol ester 
• 120047-91-8 n-butyl 4-bromobenzoate 
• 189120-01-2 2-(4-bromo-phenyl)-4,5-dihydro-oxazole 
• 914076-81-6 C₆(C₆H₄CH₃)3(C₆H₄C₃H₄NO)3 
• 914076-87-2 C₁₈H₁₅NO 

Relevant articles and documents

Illuminating a Dark Kinase: Structure-Guided Design, Synthesis, and Evaluation of a Potent Nek1 Inhibitor and Its Effects on the Embryonic Zebrafish Pronephros

NIMA-related kinase 1 (Nek1) has lately garnered attention for its widespread function in ciliogenesis, apoptosis, and the DNA-damage response. Despite its involvement in various diseases and its potential as a cancer drug target, no directed medicinal chemistry efforts toward inhibitors against this dark kinase are published. Here, we report the structure-guided design of a potent small-molecule Nek1 inhibitor, starting from a scaffold identified by kinase cross-screening analysis. Seven lead compounds were identified in silico and evaluated for their inhibitory activity. The top compound, 10f, was further profiled for efficacy, toxicity, and bioavailability in a zebrafish polycystic kidney disease model. Administration of 10f caused the expansion of fluorescence-labeled proximal convoluted tubules, supporting our hypothesis that Nek1-inhibition causes cystic kidneys in zebrafish embryos. Compound 10f displayed insignificant inhibition in 48 of 50 kinases in a selectivity test panel. The findings provide a powerful tool to further elucidate the function and pharmacology of this neglected kinase.

A Mild and Regioselective Route to Functionalized Quinazolines

A Rh-catalyzed ortho-amidation cyclocondensation sequence gave a range of 4-aminoquinazolines in high yield. The method features a remarkably mild C(sp2)-H activation step and can be exploited to rapidly access compounds with established biological activity.

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was profiled in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing.